Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
- Meiji-Kumamoto JV Becomes “Company that Can Succeed Worldwide”: Kaketsuken Chief
December 19, 2017
- MHLW Approves Proposed Reforms to Allow the Export of Plasma Fraction Products
December 19, 2017
- Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
- Modified PMP Plan Reflects Some Industry Requests, but Not Sufficient: Chuikyo Pharma Rep
December 14, 2017
- Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached
December 14, 2017
- MHLW Plans to Establish Related Information Service for Improving Drug Distribution
December 14, 2017
- Chuikyo Members Snub Possible Change to 14-Day Prescription Limit
December 13, 2017
- LDP Lawmaker Prods MHLW to Include 4th or Later Drugs in PMP Coverage Too
December 13, 2017
- Japan and Taiwan to Conduct Pilot Project to Accelerate New Drug Reviews in Taiwan by Using PMDA’s Review Reports
December 13, 2017
- Abilify, Lixiana and Others under PMDA Risk Review
December 12, 2017
- MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo
December 11, 2017
- First Generics for 8 APIs, AGs of Avapro, Talion Receive Listing on Dec. 8
December 8, 2017
- Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices
December 8, 2017
- Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope
December 7, 2017
- (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- ICH Completes Guidelines for Multiregional Clinical Trials; Could Accelerate Simultaneous Global Development
December 6, 2017
- MHLW Reviewing PMP in View of People’s Understanding: Health Insurance Chief
December 6, 2017
- Checklist Presented for Excluding Foundation-Funded Programs from “Specified Clinical Research”
December 6, 2017
- NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…